RBC and plasma levels of haloperidol and clinical response in schizophrenia. 1982

R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson

The authors conducted a fixed-dose study of haloperidol blood levels and clinical response in schizophrenic in patients and found that those with steady-state RBC haloperidol levels in the range of 2.4--5.4 ng/ml showed greater improvement than those with lower or higher levels. They found a similar , although nonsignificant, curvilinear relationship between plasma haloperidol levels and clinical response. These findings suggest that the relationship between haloperidol blood levels and clinical response fits a therapeutic window for the treatment of schizophrenia.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
January 1983, Psychopharmacology,
R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
October 1982, Psychopharmacology bulletin,
R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
August 1989, Biological psychiatry,
R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
March 1994, Progress in neuro-psychopharmacology & biological psychiatry,
R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
December 1987, Archives of general psychiatry,
R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
January 1985, Psychopharmacology bulletin,
R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
December 1990, Journal of clinical psychopharmacology,
R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
January 1984, European archives of psychiatry and neurological sciences,
R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
January 1985, Psychopharmacology bulletin,
R C Smith, and G Vroulis, and A Shvartsburd, and R Allen, and N Lewis, and J C Schoolar, and M Chojnacki, and R Johnson
August 1985, Archives of general psychiatry,
Copied contents to your clipboard!